It has recently been demonstrated that in vivo administration of murine interleukin 12 (IL-12) to mice results in augmentation ofcytotoxic natural killer (NK)/lymphocyte-activated killer cell activity, enhancement of cytolytic T cell generation, and induction of interferon 7, secretion. In this study, the in vivo activity of murine IL-12 against a number of murine tumors has been evaluated. Experimental pulmonary metastases or subcutaneous growth of the B16F10 melanoma were markedly reduced in mice treated intraperitoneally with IL-12, resulting in an increase in survival time. The therapeutic effectiveness of IL-12 was dose dependent and treatment of subcutaneous tumors could be initiated up to 14 d after injection of tumor cells. Likewise, established experimental hepatic metastases and established subcutaneous M5076 reticulum cell sarcoma and Renca renal ceU adenocarcinoma tumors were effectively treated by IL-12 at doses which resulted in no gross toxicity. Local peritumoral injection of IL-12 into established subcutaneous Renca tumors resulted in regression and complete disappearance of these tumors. IL-12 was as effective in NK ceLl-deficient beige mice or in mice depleted of NK cell activity by treatment with antiasialo GM1, suggesting that NK cells are not the primary cell type mediating the antitumor effects of this cytokine. However, the efficacy of IL-12 was greatly reduced in nude mice suggesting the involvement of T cells. Furthermore, depletion of CD8 + but not CD4 + T cells significantly reduced the efficacy of IL-12. These results demonstrate that IL-12 has potent in vivo antitumor and antimetastatic effects against murine tumors and demonstrate as well the critical role of CD8 + T cells in mediating the antitumor effects against subcutaneous tumors.
H
uman IL-12 is a disulfide-bonded heterodimeric cytokine consisting of a 40-and a 35-kD subunit (1, 2) . The genes for this cytokine have been cloned (3, 4) and purified recombinant protein has been produced. A number of biological properties of human IL-12 have been evaluated in vitro. Among its properties are the ability to act as a NK cell and T cell growth factor (5-7), to enhance NK/LAK cell cytolytic activity (1, (7) (8) (9) , to augment cytolytic T cell responses (9) , and to induce secretion of cytokines, particularly IFN-3,, from T and NK cells (1, 10) . Since both T and NK cells have been implicated as antitumor effector cells (11) and IFN-3' has been shown to have antitumor activity in animals (12, 13) , IL-12 has the potential to be used as an immunomodulatory cytokine in the therapy of malignancies.
The ability to test the in vivo activities of IL-12 have been limited since human IL-12 is inactive on murine cells, but recently the genes for murine IL-12 have been cloned (14) . Injection of mice with recombinant murine IL-12 augments NK activity, enhances allogeneic cytolytic T cell responses, and induces secretion of IFN-% thus confirming the previously described in vitro activities of IL-12 (Gately, M. K., R. R. Warrier, S. Honasoge, D. A. Faherty, S. E. Connaughton, T. D. Anderson, U. Sarmiento, B. R. Hubbard, and M. Murphy, manuscript submitted for publication). Based on these in vivo results, the antitumor and antimetastatic activities of murine IL-12 against a number of murine malignancies have been evaluated. We demonstrate in this study that systemic administration of IL-12 can inhibit the growth of both established subcutaneous tumors and experimental pulmonary or hepatic metastases, and that local peritumoral injections of IL-12 can result in regression of established subcutaneous tumors. Based on results obtained using mice deficient in lymphocyte subsets and antibody depletion experiments, the antitumor efficacy of IL-12 is mediated primarily through CD8 + T cells.
Materials and Methods
Mice. C57BL/6, C57BL/6 bg/bg beige, C57BL/6 bg/+ heterozygous beige control and BALB/c mice, 6-8 weeks of age, were purchased from The Jackson Laboratories, (Bar Harbor, ME were maintained in vitro in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 100/zg/ml streptomycin, 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, 25 mM NaHCO3, and 60 #g/ml t-glutamine. M5076, a reticulum cell sarcoma (12, 17) , was maintained as a stationary suspension culture in RPMI 1640 supplemented with 17% equine serum (Hyclone Laboratories, Inc., Logan, UT), 1 mM sodium pyruvate, 50/zg/ml gentamicin, glutamine, penicillin, and streptomycin. All reagents for cell culture were purchased from GIBCO BILL (Gaithersburg, MD) unless otherwise designated. All cell lines were found to be free of mycoplasma and viruses as above.
RecombinantMurine 11-,12. Murine riD12 was expressed in CHO cells that had been stably transfected with the IL12 p40 and p35 cDNAs and was purified as previously described (Gately, M. K., et al., manuscript submitted for publication). SDS-PAGE analysis of the purified IL-12 indicated it to be ~95% pure with a small amount of contaminating II,12 p40 monomer. Monomeric IL-12 p40 does not bind to the II.-12 receptor (18) and lacks biological activity (3, 4) . Contamination by endotoxin, as assessed by the Limulus amebocyte assay, was <5 EU/mg Ib12. The sp act of purified murine riD12, as determined by its ability to cause proliferation of human PHA blasts (18) , was "~7 x 106 U/mg protein.
For administration to mice, rlL-12 was diluted in PBS containing 100/~g/ml mouse serum albumin (Miles Scientific, Naperville, IL or Sigma Chemical Co., St. Louis, MO).
Tumor Experiments. Exponentially growing tumor cells were harvested by brief trypsinization (B16F10 and Renca), washed, and injected subcutaneously or intravenously into groups of 10 mice on day 0, and intraperitoneal treatment with various doses of I1.-12 once per day five times per week was initiated between days I and 28, depending on the experiment. Specific protocols are presented in the legends of individual experiments. The diameters of subcutaneous tumors were measured twice weekly with calipers, and volume was calculated by the formula: Vol = (longest diameter) x (shortest diameter) z (Gately, M. K., et al., manuscript submitted for publication). For metastasis experiments, approximately 3 wk after intravenous injection of tumor cells, mice were killed and the number of metastases enumerated as previously described (15) . Statistical evaluation of the data was performed using the nonparametric one-tailed Mann-Whitney U test (17) . Experiments were repeated two to eight times, and data from representative experiments are presented.
Antibody Depletion Experiments. Antiasialo GM1 (anti-ASGM1) was purchased from Biochemical Diagnostics, Inc. (Edgewood, NY). Mice were injected intraperitoneally with 0.4 ml of 1:5 dilution of anti-ASGM1 or normal rabbit serum on the days indicated. Under these conditions of treatment with antiasialo GM1 splenic NK activity, is reduced to undetectable levels (17) . Anti-CD4 (clone GK1.5, rat IgG2b) (19) and anti-CD8 (clone 2.43, rat IgG2b) (20) hybridomas were purchased from the American Type Culture Collection (l~.ockville, MD). Ascites were prepared in pristane-treated nude mice and Ig purified by the procedure of Reik et al. (21) . Mice were injected intraperitoneally with 1 mg oflg on the days indicated. Under these conditions, antibody treatment depleted >95% of the appropriate cell population in the spleen.
Results
We initially evaluated the effect of IL-12 on experimental pulmonary metastases of the B16F10 melanoma. After intravenous injection with tumor cells on day 0, C57BL/6 mice were treated intraperitoneaUy beginning on day 1 with varying doses of IL-12 five times per week for 3 wk. At the end of the treatment period, there was a dose-dependent inhibition of experimental metastases in the IL-12-treated mice (Fig.  1 A) . In the group receiving 1 #g per injection, the median number of metastases was reduced to 41 compared with 200 in the diluent-treated mice (p <0.005). To determine if treatment could be initiated at a time when metastases were al- (Fig. 2 A) . At all doses tested, no gross toxicity was evident and all animals survived the therapy, although at the 5 #g dose some lethargy was ob- diluent-treated control mice. Although tumor growth was suppressed for a prolonged time by IL-12 treatment, no "cures" were obtained, and tumors eventually grew, resulting in death of the animals. To evaluate the effect of IL-12 against larger B16F10 tumors, treatment with 1/zg of IL-12 per injection was delayed until day 14. As seen in Fig. 2 C, tumors grew progressively in control animals through day 29, at which point all animals had died. In contrast, the growth of tumors in mice treated with IL-12 was greatly diminished. These results demonstrate that IL-12 has marked antitumor activity against subcutaneous B16F10 tumors.
Since antitumor activity of IL-12 had only been demonstrated against the B16F10 melanoma, the antitumor efficacy of IL-12 was next evaluated against additional tumors. After intravenous injection of M5076 reticulum ceil sarcoma, experimental hepatic metastases are formed (17) . As seen in Fig.  3 (Fig.  3 B) . In these IL-12-treated animals, spontaneous hepatic metastases are also greatly reduced (Brenda, M. J., and T. D. Anderson, unpublished observation). Therefore, the antitumor activity of IL-12 is evident against both subcutaneous tumor growth and experimental hepatic metastases of the M5076 reticulum cell sarcoma.
To evaluate further the antitumor activity of IL-12, mice were injected subcutaneously with the Renca renal cell adenocarcinoma and treated with IL-12. The Renca renal cell adenocarcinoma is a murine tumor of spontaneous origin in BALB/c mice that mimics histologically renal cell carcinoma in humans (16) and is sensitive to various cytokines in vivo (16, 22) . Beginning on day 14, intraperitoneal treatment of mice with IL-12 resulted in a dramatic inhibition of tumor growth (Fig. 4 A) , although complete regression of tumors was not observed. Since it has previously been reported that regression of the Renca tumor occurs after transfection of IL-4 into this tumor cell (22) , mice bearing day 14 subcutaneous Renca tumors were injected peritumorally with 1/~g of IL-12. As seen in Fig. 4 B, tumors were markedly inhibited and, in fact, tumor regression occurred with no tumor detectable in 70% of treated mice after 60 d. Upon rechailenge with tLenca cells alone, tumor growth is greatly inhibited in these survivors (data not shown). Thus, IL-12 has pronounced antitumor activity against the Renca renal cell adenocarcinoma and can, under certain conditions, result in regression of established tumors.
Since IL-12 has been demonstrated to have effects on both NK and T cells (1-10, 14, and Gately, M. K., et al., manuo script submitted for publication), the antitumor activity of IL-12 might be mediated through either of these cell types. To determine if the antitumor efficacy of IL-12 was primarily mediated through NK cells, its activity was evaluated against (Fig. 5) . To confirm and extend these results, Renca tumor-bearing BALB/c mice were depleted of NK cells using anti-ASGM1 and treated with IL-12. No loss of IL-12-induced antitumor efficacy was observed in these NK cell-depleted mice (Fig. 6 ). Taken together, these results strongly suggest that the antitumor efficacy of IL-12 is not mediated through NK ceils.
To evaluate the potential role of T cells on IL-12-induced antitumor efficacy, the antitumor effect of IL-12 was tested against B16F10 tumors in nude mice (Fig. 7 A) . Although there was a slight dday in tumor growth, the effect of IL-12 was markedly diminished compared with that observed in euthymic mice. The greatly reduced activity of IL-12 was also obtained in BALB/c nude mice bearing syngeneic Renca tumors (Fig. 7 B) . To evaluate further the requirement for T ceils in mediating IL-12-induced antitumor efficacy and to determine the role ofT cell subsets, Renca tumor-bearing mice were treated with anti-CD4 or anti-CD8 antibodies. As seen in Fig. 8 , the activity of IL-12 is not affected in mice depleted of CD4 + T ceils but substantially, although not The mechanism through which IL-12 exerts its antitumor activity is at present unknown, but based on its established in vivo activities several potential hypotheses can be suggested. IL-12 may have direct growth inhibitory effects on tumor cells. This is unlikely since addition of IL-12 in vitro to the murine tumor cells used in our studies resulted in no inhibition of tumor cell proliferation (Brunch, M. J., and L. Luistro, unpublished observation) and there is reduced activity of this cytokine against tumors in nude mice (Fig. 7) . However, IL-12 has been shown to induce production and secretion of IFN-y (1, 10, and Gately, M. K., et al., manuscript submitted for publication), which might then in turn inhibit proliferation of tumor cells (24) . Such a proposed mechanism would be consistent with the lack of direct in vitro antiproliferative activity on tumor cells and the observed in vivo efficacy of IL-12. IFN-3' has been previously shown to have activity in vivo against murine tumors, although not to the extent observed with IL-12 (12, 13) . Both T and NK cells can produce IFN-3, in response to IL-12 in vitro (1, 10) , but if this hypothesis is correct, it would appear that T cell production of IFN-3/ is critical to the antitumor activity of IL-12 in vivo because the efficacy of IL-12 is greatly reduced in athymic nude mice (Fig. 7) . It is unlikely that the antitumor efficacy of IL-12 is directly an effect of the level of IFN-3' induced since IL-12 induces an approximately fivefold higher level of IFN-y in nude mice than in euthymic mice (Hendrzak, J., and M. Brunch, unpublished observation) but IL-12 has a substantially reduced antitumor effect in nude mice (Fig. 7) . IL-12 retains some activity in nude mice, which may reflect the induction of IFN-3, or other cytokines. Treatment of mice with antibodies to IFN-'y may resolve some of these issues but in other studies (25, 26) this approach yielded conflicting results. Recently, IFN-3' knock out mice have been developed (27) and the evaluation of the antitumor activity of IL-12 in these animals could prove interesting.
In addition to secretion of IFN-% stimulation of human NK or T cells with human IL-12 results in secretion of tumor necrosis factor (6), which can have antiproliferative effects on tumor cells (28) . Recent data using cells from SCID mice demonstrate that incubation of these cells with murine IL-12 resulted in no secretion of TNF in vitro using conditions that induced IFN-y (29) . Likewise, in preliminary experiments, no TNF was induced from normal murine spleen cells stimulated by murine IL-12 in vitro (Hendrzak, J., and M. Brunch, unpublished observations). Thus, it appears that IL-12 is a relatively poor inducer of TNF in mice. However, the contribution of TNF or potentially other cytokines in mediating the antitumor effects of IL-12 in vivo needs to be addressed in future experiments.
IL-12 can both enhance the growth (5-7) and augment the cytolytic activity (1, 7-9, and Gately, M. K., manuscript submitted for publication) of NK/LAK and T cells. Thus, the antitumor efficacy of IL-12 might be mediated through stimulation of one or both these lymphocyte populations. It is unlikely that NK cells are primarily involved since the antitumor activity of IL-12 is maintained in both NK cell-deficient beige mice (Fig. 5) and in mice depleted of NK cells with anti-ASGM1 (Fig. 6) . However, T cells appear to be necessary to obtain maximal effects since the efficacy of IL-12 treatment is greatly diminished in nude mice (Fig. 7) . Under other experimental conditions, the antitumor activity of a number of cytokines has been reported to be dependent upon T cells (22, 30, 31) . It has been suggested that IL-12 promotes the development of Thl cells (32, 33) , and these in turn may positively regulate the expansion and/or activation of other lymphoid cell populations. After depletion of T cell subsets with mAbs, the efficacy of IL-12 was decreased in mice depleted of CD8 + T cells but remained intact in mice depleted of CD4 + T cells (Fig. 8) . These results indicate that CD8 + T cells are the critical cell type for mediating the antitumor efficacy of IL-12. The efficacy of IL-12 is not completely eliminated in CD8 + T cell-depleted mice. This finding may reflect the effect of IL-12 on the few remaining CD8 + T cells or on other cell types, such as macrophages. It appears that CD4 + T cells are not necessary for mediating the antitumor effects of IL-12, which is puzzling in light of the effects of IL-12 on CD4 + Thl cells (32, 33) . However, since IL-12 also stimulates cytokine secretion from NK cells (1, 10) , the cytokine-secreting function of CD4 + T cells may be replaced by NK cells under the conditions used in these tumor therapy experiments. In addition, exogenously administered IL-12 may at least partially replace any requirement for endogenously produced IL-2, since the biological activities of IL-12 substantially overlap those of IL-2.
A number of cytokines, including IFN-ol and IL-2, have been demonstrated to be active in murine tumor models (11-13, 15, 30) and, subsequently, to be useful in the treatment of human malignancies (11, 34, 35) . In contrast, with other cytokines, such as IFN-y or TNF, the activity demonstrated in animal models (11) (12) (13) 31) has not translated to successful use of these proteins for therapy of human malignancies (11, 34) . The data presented in this study clearly establish IL-12 as a cytokine that has potent antitumor and antimetastatic activities in several murine tumor models through an immunemediated, T cell-dependent mechanism. Future clinical trials with this cytokine will determine if the activity demonstrated in animals can be translated into efficacy against human malignancies.
